Skip to main content
OpenTrials

Clinical trial condition

Meningococcal Disease

Explore clinical trials studying Meningococcal Disease. Study availability and eligibility vary by location and protocol.

58 public trials 1 recruiting study
Refine in advanced search Browse all conditions

Meningococcal Disease trial results

Completed

Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine

NCT01345721

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +7 more
Locations
  • Dr. Johannes Kandzora and Dr. Kathrin Kandzora Am Teich 11, Neumuenster, Germany
  • Bogda-Maria Kniese, Boyneburgstr 7, Eschwege, Germany
  • Dr Goertz Martin Kimmig GroBbottwarer Str 47, Oberstenfeld, Germany
  • Dr med Walter Otto Heinrichstrasse 16 A, Fulda, Germany
View Trial Details
Completed

Assessment of Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10

NCT01148524

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Central Nervous System Bacterial Infections, +13 more
Locations
  • Centro de Salud Lo Barnechea Santiago, Chile
  • Centro para vacunas en desarrollo. Hospital de Niños Roberto del Río Santiago, Chile
  • Escuela de Medicina de la Universidad de Valparaíso Santiago, Chile
  • Hospital Luis Calvo Mackenna Santiago, Chile
View Trial Details
Completed

Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12

NCT00944034

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Central Nervous System Bacterial Infections, +13 more
Locations
  • Avenue Albert 1er 185, 5000 Namur, Belgium
  • Avenue Hippocrate 10, 1200 Brussels, Belgium
  • Laarbeeklaan 101, 1090 Brussels, Belgium
  • Lindendreef 1, 2020 Antwerpen, Belgium
View all 72 locations
View Trial Details
Completed

Testing the Use of Prompts to Increase Adolescent Immunization Rates

NCT01984125

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Bordetella Infections, +17 more
Locations
  • University of Arkansas - Arkansas Children's Hospital Little Rock, Arkansas, United States
  • Wilmington Hospital Health Center Wilmington, Delaware, United States
  • University of Florida Gainesville, Florida, United States
  • Children's Memorial Hospital - Northwestern University Chicago, Illinois, United States
View all 22 locations
View Trial Details
Completed

Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy Toddlers

NCT01434680

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Central Nervous System Bacterial Infections, +13 more
Locations
  • NZOZ Bioscience Sp zoo Ul Czerkaska, Bydgoszcz, Poland
  • Department Infection Disease ZOZ Dept Infection Disease ZOZ, Debica, Poland
  • Centrum Medyczne Graniczna Sp zoo Ul Graniczna 45, Katowice, Poland
  • NZOZ HIPOKRATES IIspzoo Ul Strzelecka 2, Krakow, Poland
View Trial Details
Completed

Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects.

NCT02141516

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, +13 more
Locations
  • 12, Novartis Investigational Site Florence, Italy
  • 11, Novartis Investigational Site Genova, Italy
  • 10, Novartis Investigational Site Milan, Italy
  • 14, Novartis Investigational Site Padova, Italy
View all 20 locations
View Trial Details
Completed

Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180)

NCT01992536

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +4 more
Locations
  • Site 23, Alabama Clinical Therapeutics 806 St. Vincent's Drive, Suite 615 Birmingham, Alabama, United States
  • Site 24, Madera Family Medical Group 1111 West 4th Street Madera, California, United States
  • Site 25, Center for Clinical Trials LLC 16660 Paramount Blvd, Suite 301 Paramount, California, United States
  • Site 28, Kentucky Pediatric/Adult Research 201 South 5th Street Bardstown, Kentucky, United States
View all 13 locations
View Trial Details
Completed

A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years

NCT01339923

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Central Nervous System Bacterial Infections, +13 more
Locations
  • Site 55 - Instituto de Medicina Integral Prof. Fernando Figueira (IMIP) Rua Dos Coelhos, 300 - Boa Vista, Recife/PE, Brazil
  • Site 54- Associação Obras Sociais Irmã Dulce, Avenida Bonfim, nº 161 Largo de Roma, Salvador/BA-CEP, Brazil
  • Site 53 - CRIE UNIFESP Rua Borges Lagoa 770, São Paulo, Brazil
  • Site 50 - Associacao Fundo de Incentivo a Psicofarmacologia Rua Marselhesa 500 Vila Clementino, São Paulo, Brazil
View all 26 locations
View Trial Details

Related conditions